scholarly journals Comparative analysis of the efficiency of the selective b-blocker nebivolol and the angiotensin II receptor blocker valsartan in men with hypertension, metabolic syndrome, and erectile dysfunction

2013 ◽  
Vol 4 (2) ◽  
pp. 57-66
Author(s):  
S. V Nedogoda ◽  
A. S Salasyuk ◽  
I. N Barykina ◽  
A. A Ledyaeva ◽  
V. V Tsoma ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Erectile Dysfunction ◽  
Metabolic Parameters ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Group Evaluation ◽  
Parallel Group ◽  
Quality Of Life Indicators ◽  
Negative Effect ◽  
Positive Effect

Objective: to evaluate the antihypertensive efficacy and effect of nebivolol and valsartan on metabolic parameters and erective function in patients with hypertension, metabolic syndrome, and erectile dysfunction. Subjects and methods. A 12-week randomized, blind, controlled, parallel-group, comparative (nebivolol versus valsartan) trial enrolled 40 patients with hypertension, metabolic syndrome, and erectile dysfunction. Results. There were no significant differences between the drugs in their antihypertensive efficiency. Nebivolol exerted a more pronounced positive effect on cardioand angioprotection and lipid and carbohydrate metabolic parameters. It had no negative effect on metabolic parameters. Therapy with nebivolol versus valsartan produced a pronounced positive effect on blood androgen levels and erectile function. Moreover, the quality-of-life indicators also showed a significant improvement in the nebivolol group. Evaluation of the tolerability and adverse reactions of the drugs demonstrated no side effects in both groups.

scholarly journals Effect of angiotensin II receptor antagonists on left ventricular hypertrophy, vascular elasticity, and lipid and carbohydrate metabolic parameters in metabolic syndrome

2013 ◽  
Vol 10 (2) ◽  
pp. 27-33
Author(s):  
S V Nedogoda ◽  
A S Salasyuk ◽  
T A Chalyabi ◽  
I N Barykina ◽  
D A Pocheptsov ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Left Ventricular ◽  
Metabolic Parameters ◽  
Antihypertensive Activity ◽  
Angiotensin Ii Receptor ◽  
Anthropometric Parameters ◽  
Parallel Group ◽  
Obesity Therapy ◽  
Positive Effect

Aim: to evaluate the antihypertensive efficacy and effects of telmisartan and losartan on metabolic parameters in patients with arterial hypertension and metabolic syndrome. Subjects and methods. A blind randomized, controlled, parallel group comparative (telmisartan versus losartan for 24 weeks) trial enrolled 60 patients with arterial hypertension and metabolic syndrome. Results. Significant differences were found in favor of telmisartan in antihypertensive activity, cardio-, angio-, and nephroprotection and ability to improve lipid and carbohydrate metabolic parameters. Only did telmisartan reduce the manifestations of insulin resistance and hyperleptinemia in patients with hypertension and obesity. Therapy with telmisartan versus losartan exerted a pronounced positive effect on anthropometric parameters and fat deposition rate. The drugs were found to be well tolerated and to cause no adverse reactions in both groups.

scholarly journals Treatment of hypertension in obese patients: focus on telmisartan

2018 ◽  
Vol 17 (6) ◽  
pp. 69-76 ◽  
Author(s):  
I. E. Deneka ◽  
A. V. Rodionov ◽  
V. V. Fomin
Keyword(s):  
Arterial Hypertension ◽  
Inflammatory Process ◽  
Angiotensin Ii Receptor Blocker ◽  
Obese Patients ◽  
Angiotensin Ii Receptor ◽  
Treatment Of Hypertension ◽  
Mechanisms Of Development ◽  
Positive Effect

The article discusses the role of telmisartan in the treatment of arterial hypertension in patients with metabolic syndrome. Telmisartan is second-generation type 1 angiotensin II receptor blocker, which has unique pleiotropic effects due to partial affinity for receptors that activate the proliferation of subtype y peroxisomes (PPARy) located in adipose tissue. The interrelation of metaflamation, a specific chronic inflammatory process with pathogenetic mechanisms of development of cardiovascular diseases, including arterial hypertension, is also described in study. The role of the adiponectin peptide is considered, which synthesis is stimulated by partial PPARy receptor agonists (as mentioned above — telmisartan). It has a positive effect on fat and carbohydrate metabolism, as well as cardioprotective properties. The conclusion contains the results of numerous randomized studies and meta-analyzes confirming the high efficacy of telmisartan in the treatment of arterial hypertension in patients with morbid obesity.

scholarly journals THE EFFECTIVENESS OF CARVEDILOL AND EPROSARTAN IN PATIENTS WITH METABOLIC SYNDROME AND CHRONIC HEART FAILURE

2014 ◽  
Vol 13 (2) ◽  
pp. 46-50
Author(s):  
R. L. Dashnamirov
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Heart Rate ◽  
Chronic Heart Failure ◽  
Exercise Tolerance ◽  
Functional Class ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Traditional Treatment ◽  
Alpha Beta

Аim. of the study was to assess the effectiveness of carvedilol and eprosartan in addition to the traditional treatment (Nitrosorbid 30mg/day + Digoxin 0.25mg/day + TromboASS 100mg/day + Atorvastatin 20mg/day + Furosemid 40mg/day + Verospiron 50mg/day + Atenolol 12.5–25 mg/day) in patients with metabolic syndrome and chronic heart failure.Materials and methods. 91 patients with MS and CHF included sharing mentioned criteria. Carvedilol in doses of 6,25 ÷ 25 mg/day and eprosartan in doses of 300 ÷ 600 mg/day were administered in addition to the traditional treatment.Results. After 12 months of treatment systolic BP decreased by 23.6% and diastolic by 17.2%. Heart rate decreased by 23.1%, and exercise tolerance increased by 22.3%. Dynamics of the presented indicators are statistically significant.Conclusion. Administration of an alpha-beta blocker carvedilol and angiotensin II receptor blocker eprosartan in the above dosages promote the longest remission of heart failure, improvement in functional class and regression of pathological remodeling.

1236: Does Erectile Dysfunction Predict Risk of Metabolic Syndrome in Aging Men? Results from the Massachusetts Male Aging Study

2005 ◽  
Vol 173 (4S) ◽  
pp. 335-335 ◽  
Author(s):  
Ridwan Shabsigh ◽  
Andre B. Araujo ◽  
Amy B. O'Donnell ◽  
John B. McKinlay
Keyword(s):  
Metabolic Syndrome ◽  
Erectile Dysfunction ◽  
Aging Men ◽  
Aging Study

1237: Erectile Dysfunction (ED) Evaluation Through the Metabolic Syndrome Window

2005 ◽  
Vol 173 (4S) ◽  
pp. 335-336 ◽  
Author(s):  
Omer Demir ◽  
Tevfik Demir ◽  
Aykut Kefi ◽  
Abdurrahman Comlekci ◽  
Sena Yesil ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Erectile Dysfunction ◽  
The Metabolic Syndrome
Sign in / Sign up

Export Citation Format

Share Document